Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers

In our article, we evaluated the regulatory effects of the infusions of rituximab, a monoclonal antibody directed against CD20(+) B cells, on the serum matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) levels in patients with active rheumatoid arthritis (RA) not...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimiuk, Piotr Adrian, Domysławska, Izabela, Sierakowski, Stanisław, Chwiećko, Justyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article - Emerging Hypotheses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365285/
https://www.ncbi.nlm.nih.gov/pubmed/25190551
http://dx.doi.org/10.1007/s00296-014-3112-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365285/
https://www.ncbi.nlm.nih.gov/pubmed/25190551
http://dx.doi.org/10.1007/s00296-014-3112-1

Ejemplares similares